Read all posts
www.cnbc.com

Has Biogen found the ‘Goldilocks’ dose for Alzheimer’s drug?

Biogen is looking to settle on one key thing: the perfect dose for its experimental Alzheimer's drug.

Read the article on CNBC

Dr. Sears Comments:

Dr. Barry Sears

Not surprisingly, the announced data for this drug study was mixed.  That is pharma-talk for saying it didn’t work very well.

 

Leave a Reply

Your email address will not be published. Required fields are marked *